DE370889-1057-4355-AFD8-CCFCDC6CD00F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 27.201051248357423
- age_years
- 69
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.981 |
| 2 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.979 |
| 3 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.977 |
| 4 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.977 |
| 5 | A9B59C46-7F32-4DD1-9649-B1788CA5E909 | — | — | 0.975 |
| 6 | SRR934921 | — | — | 0.974 |
| 7 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.974 |
| 8 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.974 |
| 9 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.973 |
| 10 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.973 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.727 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.625 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.575 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.567 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.565 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.564 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.532 | Idelalisib | — uncovered |
| APOPTOSIS | 0.529 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.509 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.505 | Remibrutinib | — uncovered |
| HYPOXIA | 0.502 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.493 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.488 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.479 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.474 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.473 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.460 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.441 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.428 | Idelalisib | — uncovered |
| COMPLEMENT | 0.419 | Inavolisib | — uncovered |